JATT Acquisition (JATT) Competitors $4.17 +0.24 (+6.11%) As of 10/6/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock JATT vs. VOR, FHTX, HUMA, NGNE, ALLO, IMRX, ABEO, IMMP, RENB, and TNYAShould you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include Vor Biopharma (VOR), Foghorn Therapeutics (FHTX), Humacyte (HUMA), Neurogene (NGNE), Allogene Therapeutics (ALLO), Immuneering (IMRX), Abeona Therapeutics (ABEO), Prima BioMed (IMMP), Lunai Bioworks (RENB), and Tenaya Therapeutics (TNYA). These companies are all part of the "pharmaceutical products" industry. JATT Acquisition vs. Its Competitors Vor Biopharma Foghorn Therapeutics Humacyte Neurogene Allogene Therapeutics Immuneering Abeona Therapeutics Prima BioMed Lunai Bioworks Tenaya Therapeutics JATT Acquisition (NYSE:JATT) and Vor Biopharma (NASDAQ:VOR) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations. Do insiders and institutionals believe in JATT or VOR? 48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by company insiders. Comparatively, 0.5% of Vor Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media refer more to JATT or VOR? In the previous week, Vor Biopharma had 10 more articles in the media than JATT Acquisition. MarketBeat recorded 11 mentions for Vor Biopharma and 1 mentions for JATT Acquisition. Vor Biopharma's average media sentiment score of 0.21 beat JATT Acquisition's score of 0.00 indicating that Vor Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment JATT Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vor Biopharma 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is JATT or VOR more profitable? Vor Biopharma's return on equity of 0.00% beat JATT Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets JATT AcquisitionN/A -49.58% 2.84% Vor Biopharma N/A N/A N/A Which has preferable earnings and valuation, JATT or VOR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJATT AcquisitionN/AN/A$6.85MN/AN/AVor BiopharmaN/AN/AN/A-$273.20-0.12 Do analysts rate JATT or VOR? Vor Biopharma has a consensus price target of $113.83, indicating a potential upside of 240.82%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Vor Biopharma is more favorable than JATT Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vor Biopharma 1 Sell rating(s) 5 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.36 SummaryVor Biopharma beats JATT Acquisition on 7 of the 9 factors compared between the two stocks. Get JATT Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JATT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JATT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JATT vs. The Competition Export to ExcelMetricJATT AcquisitionBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$71.93M$354.70M$6.09B$22.02BDividend YieldN/AN/A5.69%3.58%P/E RatioN/AN/A85.3529.86Price / SalesN/A447.00539.7865.87Price / Cash27.0822.4437.9224.43Price / Book-7.873.9213.014.64Net Income$6.85M-$133.30M$3.30B$1.01B7 Day Performance3.22%3.37%4.34%0.44%1 Month Performance88.69%18.77%9.49%3.13%1 Year Performance4.77%22.54%84.83%15.30% JATT Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JATTJATT AcquisitionN/A$4.17+6.1%N/A-2.1%$71.93MN/A0.003High Trading VolumeVORVor Biopharma3.2274 of 5 stars$40.50+3.2%N/AN/A$277.43MN/A-0.15140Analyst ForecastInsider TradeFHTXFoghorn Therapeutics2.0712 of 5 stars$4.86-1.4%$11.00+126.3%-40.8%$276.43M$22.60M-4.11120News CoverageAnalyst ForecastHUMAHumacyte2.8269 of 5 stars$1.73-2.0%$9.29+438.3%-69.5%$274.77M$1.57M-3.86150Trending NewsAnalyst ForecastOptions VolumeNGNENeurogene1.2493 of 5 stars$18.92+5.3%$46.17+144.0%-48.7%$274.77M$930K-4.4790News CoverageAnalyst ForecastALLOAllogene Therapeutics2.7399 of 5 stars$1.24-0.4%$8.44+583.8%-46.4%$274.02M$20K-1.11310Analyst ForecastGap UpIMRXImmuneering3.9142 of 5 stars$6.58+3.4%$16.40+149.4%+172.0%$271.66M$320K-3.4660Analyst ForecastShort Interest ↑ABEOAbeona Therapeutics4.342 of 5 stars$5.24-0.8%$19.50+272.1%-15.2%$268.96M$3.50M7.4990News CoverageAnalyst ForecastIMMPPrima BioMed1.0269 of 5 stars$1.83+1.1%$7.00+282.5%-0.2%$267.89M$6.69M0.002,021News CoveragePositive NewsAnalyst ForecastRENBLunai Bioworks0.6671 of 5 stars$1.54+21.7%N/A-62.6%$265.24MN/A-2.0020Gap DownTNYATenaya Therapeutics3.2844 of 5 stars$1.63-3.3%$6.25+284.6%+5.8%$265.17MN/A-1.69110News CoverageAnalyst Forecast Related Companies and Tools Related Companies VOR Alternatives FHTX Alternatives HUMA Alternatives NGNE Alternatives ALLO Alternatives IMRX Alternatives ABEO Alternatives IMMP Alternatives RENB Alternatives TNYA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:JATT) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JATT Acquisition Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share JATT Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
